Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer (Stage IIIb or IV) with a Higher T Stage (> T2)

Publisher： Karger

E-ISSN： 1423-0232|63|2|173-179

ISSN： 0030-2414

Source： Oncology, Vol.63, Iss.2, 2002-09, pp. : 173-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression

By  

Respiration, Vol. 70, Iss. 1, 2003-02 ,pp. : 32-35

Karger

Access to resources Recommend Favorite

Paclitaxel, Carboplatin and Gemcitabine Combination as Induction Chemotherapy for Stage IIIA N2 Bulky Non-Small Cell Lung Cancer

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 295-300

Karger

Access to resources Recommend Favorite

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 435-443

Karger

Access to resources Recommend Favorite

EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Report of a 3-Year Compassionate Use Experience with Gefitinib in Stage IIIB/IV Outpatients

By  

Oncology Research and Treatment, Vol. 28, Iss. 12, 2005-12 ,pp. : 623-627

Karger

Access to resources Recommend Favorite

Effect of the BCL2 Gene Polymorphism on Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients Who Received Chemotherapy

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 214-218

Karger

Access to resources Recommend Favorite